Sat.Jun 05, 2021 - Fri.Jun 11, 2021

article thumbnail

Novo’s obesity drug has serious warnings and barriers to overcome

World of DTC Marketing

SUMMARY: The media headlines promise weight loss for diabetes patients, but Norvo’s new drug is in the same class as other drugs and carries many warnings. Can diabetes patients really stay adherent to a drug for 63 weeks in which 85% of patients report GI side effects and will insurance cover the cost? The headlines read “FDA approves obesity drug that helped people cut weight 15%” But buyer beware.

article thumbnail

Episode – Navigating Product Adoption Pitfalls with Ted Newill

Medical Device Success

Reading time: 2 – 4 minutes. There are numerous pitfalls that MedTech companies experience when launching a new product. This is especially true with new concept products. Patrick Kothe, host of the podcast Mastering Medical Device interviewed me to talk about these challenges. Pat is also CEO, EM Device Lab, and is in the middle of a product launch.

Medical 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Rise of Audio Social Networks – Where Pharma Can Make an Impact

Pharma Marketing Network

Anyone with a smart device has been feeling the grueling effects of social isolation and screen fatigue since the start of the COVID-19 outbreak. Recently, we have witnessed a flood of new “audio-social apps” and audio features on social media platforms, aiming to finds new ways to connect, curb loneliness and cut excessive screen exposure. What are some of these audio-focused platforms and where can pharma play a role?

article thumbnail

Product launch strategy: How to smash your sales targets

Atrivity

The pharmaceutical industry in the wake of the coronavirus pandemic has faced one of the most challenging years globally in terms of operations, scope and budget in all business areas. One of the vital elements for companies in the healthcare sector is the successful launch of new products, but achieving sales targets is a difficult task. According to a study by McKinsey & Company , approximately 66% of launches fail to meet sales expectations.

Sales 52
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

article thumbnail

Obesity represents a catastrophic failure of government policy, public health, and medicine

World of DTC Marketing

SUMMARY: Obesity has many causes, and while we would like to think the answer is as easy as people exercising more and eating less, it isn’t that simple. There is disagreement whether obesity is really considered a disease or a behavioral risk factor, similar to smoking, alcohol, and substance abuse that may lead to disease. Obesity is a multifactorial disease in which environmental conditions and several genes play an important role in developing this disease.

article thumbnail

The latest Real-world evidence (RWE) trends in pharma

Clarify Health

As reliance on clinical trial data alone becomes considered inadequate to thoroughly assess the effectiveness of therapies, applications for real-world evidence (RWE) are increasing. Real-world evidence companies are partnering with regulators for registration decision-making and the monitoring of adverse events. Payers use RWE for coverage and payment decisions.

Pharma 52

More Trending

article thumbnail

Your HCP marketing just became harder, a lot harder

World of DTC Marketing

Key Points: Trust in the CDC and FDA has decreased dramatically during the COVID-19 pandemic among health care professionals, according to a new WebMD/Medscape poll. Out of nearly 450 U.S. doctors surveyed in the same time period, 77% said their trust in the CDC has decreased and 48% said their trust in the FDA has decreased. Health care professionals have been critical of these agencies’ decisions during the pandemic, with some concerned that their work has been politicized and now wit

Marketing 187
article thumbnail

Using the Internet to reach doctors, numbers don’t matter. What you have to say and how you say are more important.

World of DTC Marketing

SUMMARY: Several online providers promise that they can reach physicians with your message, but I would argue that numbers are only important if they can be measured against key brand objectives. Ask your target audience what THEY use and how they use it to understand each platform’s relevance. According to research from HealthLink Dimensions, more than a third of physicians reported using social networks to communicate with their professional peers, and 59% said they see the value in s

Doctors 143
article thumbnail

Pharma Marketing Network 2021 Summer Summit: Evolving the Customer Experience

Pharma Marketing Network

Join PMN on July 15th for our premier event on Customer Experience, where we will discuss best practices for moving beyond buzzwords to elevate experience and drive true patient and provider engagement based on empathy and data insights. Hear from leading Experience and Omnichannel experts from Merck, BMS, Novartis, AstraZeneca, UCB, AbbVie, and more on winning strategies to transform data into actionable strategy, elevate CX beyond campaign optimization and activate the “Engagement Matrix” in y

article thumbnail

Tom Croce

Pharma Marketing Network

Tom Croce is vice president for global patient advocacy at bluebird bio, inc., the clinical-stage biotech company that develops gene therapies for severe genetic and rare diseases. He and his team are responsible for identification and integration of patient perspectives across the entire development and commercial continuum, while ensuring meaningful company representation to patient, caregiver and advocate partners around the world.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

A sad day for us all as the FDA continues to lose credibility

World of DTC Marketing

SUMMARY: The approval of Biogen’s Alzheimer’s drug, after its advisory panel turned it down, begs the Inspector General to open an investigation into the FDA. Biogen’s $56,000 drug is proof that it was never about the science; it’s about a lifesaver for a sinking company. In the meantime, caregivers are going to put their hope in a drug that doesn’t work and in garbage science with cherry-picked data.

FDA 207
article thumbnail

The latest RWE trends from top 50 pharma

Clarify Health

On Tuesday, May 25, 2021 we hosted a workshop on “Using RWE to drive next-level commercial impact.” It was attended by 35 commercial, HEOR, and RWE experts, from over 25 different top 50 pharma companies. Manisha Shetty Gulati, COO, Clarify Health and Paul Petraro, Global Head Real World Evidence (RWE), Analytic Center of Excellence, Boehringer Ingelheim, co-led the discussion.

Pharma 52
article thumbnail

The perfect storm is coming for pharma

World of DTC Marketing

SUMMARY: One area where Republicans and Democrats agree is that drug pricing is out of control. Retail price increases for widely used brand name prescription drugs consistently exceeded the rate of general inflation between 2006 and 2020. In 2020, retail prices for 260 brand-name prescription drugs widely used by older adults increased by an average of 2.9 percent.

Pharma 187